XEBRA Study: An Observational Study of Xeloda (Capecitabine) in Combination With Docetaxel in First Line in Participants With HER2-Negative Metastatic Breast Cancer

NCT01777945 · clinicaltrials.gov ↗

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: capecitabine
DRUG: docetaxel

Sponsor

Hoffmann-La Roche